Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
about
Is there a role for carbohydrate restriction in the treatment and prevention of cancer?Diabetes and cancer: two diseases with obesity as a common risk factorDietary and pharmacological modification of the insulin/IGF-1 system: exploiting the full repertoire against cancerChemical metabolic inhibitors for the treatment of blood-borne cancersThe impact of hyperglycemia on risk of severe infections during early period of induction therapy in patients with newly diagnosed multiple myelomaThe association of diabetes and anti-diabetic medications with clinical outcomes in multiple myelomaThe role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis: a meta-analysis of prospective cohort studies.Restricting carbohydrates to fight head and neck cancer-is this realistic?Beneficial effects of ketogenic diets for cancer patients: a realist review with focus on evidence and confirmation.Safe and effective dosing of basal-bolus insulin in patients receiving high-dose steroids for hyper-cyclophosphamide, doxorubicin, vincristine, and dexamethasone chemotherapy.Chronically elevated glucose compromises myocardial mitochondrial DNA integrity by alteration of mitochondrial topoisomerase function.Diabetes and pancreatic cancer.Exenatide improves glucocorticoid-induced glucose intolerance in miceLong-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysisTransient hyperglycemia in Hispanic children with acute lymphoblastic leukemia.Glucose variability and mortality in patients with sepsis.Comorbid disease and cancer: the need for more relevant conceptual models in health services researchDifferential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells.Transient hyperglycaemia - an underestimated problem of paediatric oncohaematology.Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer.Malnutrition and obesity in pediatric oncology patients: causes, consequences, and interventions.Fasting regulates EGR1 and protects from glucose- and dexamethasone-dependent sensitization to chemotherapy.Effect of D-glucose feeding on mortality induced by sepsis.Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML)Invasive fungal infections in acute leukemia.Modeling Inpatient Glucose Management Programs on Hospital Infection Control Programs: An Infrastructural Model of ExcellenceHyperglycemia increases the complicated infection and mortality rates during induction therapy in adult acute leukemia patientsPXR ablation alleviates diet-induced and genetic obesity and insulin resistance in mice.Antecedent hyperglycemia is associated with an increased risk of neutropenic infections during bone marrow transplantation.Glucose as a prognostic factor in ovarian carcinoma.Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma.Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia.Glucocorticoid-induced hyperglycemia is prevalent and unpredictable for patients undergoing cancer therapy: an observational cohort study.A Pilot Study Evaluating Steroid-Induced Diabetes after Antiemetic Dexamethasone Therapy in Chemotherapy-Treated Cancer Patients.Undiagnosed diabetes in breast, colorectal, lung, and prostate cancer: incidence and risk factors.A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia.Understanding glycemic control in the critically ill: 2011 update.Management of hyperglycemia in hospitalized patients with renal insufficiency or steroid-induced diabetes.Awareness of the adverse effects associated with prophylactic corticosteroid use during docetaxel therapy.Hyperglycemia in patients with hematologic malignancies.
P2860
Q21245058-6360FCC8-CE71-4E2C-8CDA-E5BD9316FDD8Q26822753-703293D9-A47C-432F-B9D1-043AA8EE79C5Q28069088-1E1D7C5D-D7C2-4763-93C7-572CE7F2BCA4Q28822335-0CFCB637-E097-49F3-BA03-28A2F648F02EQ33562719-1A250AE9-5C3D-4248-A082-CB7722DE5D6EQ33994341-295C123D-8E5F-4D84-AD49-9A285D35A876Q34113485-2FE27FCF-C9CE-4A72-9B61-81C8D641DDF3Q34340949-CABD60B7-638C-451C-A4FE-26683D1CF293Q34558255-7A4BA6F5-794C-47B3-AC4D-0A633E665A2CQ34563594-8569DC34-2F14-4A43-9B86-177092C9D0F0Q34597594-470E332E-7582-42C0-9E1B-069C13AA731FQ34634263-8F6982C3-F684-4141-8136-3DA7D396685FQ34721183-E63A5164-D3C1-4E6B-A326-2E3393572667Q34976375-B690CC67-4A9F-4D2A-813F-AEAE16ACBE38Q35008062-E2C68663-79B5-4DE5-92A8-A5308307A1A4Q35222489-1F9EF9D0-9095-4068-8CD3-7459029FCB07Q35753982-C82588D4-1AEC-4E5F-898A-04AC234A76DCQ36059702-0E20B89A-C662-4E9B-A386-C03697FD5547Q36286307-EB1279D9-FBB5-4A3F-985F-E3595C9EBDF7Q36303910-EC2A8741-65A7-4F2D-9ECB-66550A9F8806Q36309946-142C8A59-3E8E-493E-BE94-101C164269CEQ36328064-04D31361-0A73-4732-887C-13AC11F54288Q36488698-24FADE29-2E8E-4010-A6BE-A029C63BD4D4Q36563582-350A7F9F-9AEC-46A5-B853-63D840700217Q36612597-1A45A316-2AEA-45FA-AD78-39E2F0A31C92Q36693950-19AACE93-98FB-4703-92BB-DD4E631FE065Q36753268-CE416EE7-330E-4F1D-970D-A8AA6B607C67Q36867493-B96D11B7-0693-4F6B-938A-BBA157925209Q36906212-F6805D67-9B7D-4F51-85BD-79E2B21C610FQ37114344-8B376BF4-85EB-4B9C-85A3-A7BDE6201C12Q37155599-F0BC3636-C114-4316-A480-F3BB7965C3E9Q37253036-2E62D98A-B448-4A52-9539-64A0B20538C2Q37364601-D2379523-248A-4B65-98FF-F1A383E31F82Q37367496-0C8754A2-DFEE-4691-95D7-46DBEC193B2DQ37651046-9B800359-8951-4FCF-8DFD-FE07F366A3C0Q37683288-8E2B02E5-BBB8-421F-8391-E0282C011B68Q37876075-D65994A3-340C-47D4-B7A9-9F008A3C8831Q38054558-C4A00FB5-228A-464D-9BC9-0D39590531FDQ38286988-770F7341-4C12-4729-8224-7EB0004EC5DAQ38341651-6CFD9E64-96CF-43B9-B8DA-AB32A713DF81
P2860
Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Relation between the duration ...... thotrexate-cytarabine regimen.
@en
Relation between the duration ...... thotrexate-cytarabine regimen.
@nl
type
label
Relation between the duration ...... thotrexate-cytarabine regimen.
@en
Relation between the duration ...... thotrexate-cytarabine regimen.
@nl
prefLabel
Relation between the duration ...... thotrexate-cytarabine regimen.
@en
Relation between the duration ...... thotrexate-cytarabine regimen.
@nl
P2093
P921
P356
P1433
P1476
Relation between the duration ...... thotrexate-cytarabine regimen.
@en
P2093
Carmen P Escalante
Deborah A Thomas
Maria E Cabanillas
Mary Ann Weiser
Sherry A Pierce
Susan M O'Brien
P304
P356
10.1002/CNCR.20071
P407
P577
2004-03-01T00:00:00Z